TB-500: What It Is and What the Science Says

TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide present in virtually all mammalian tissues. Researchers study it primarily for its role in cell migration, new blood vessel formation, and modulation of the inflammatory response. PeptoClinic supplies TB-500 as Research Use Only material, accompanied by an analytical report from Janoshik Analytical.

Peptide structure and origin

Thymosin Beta-4 was first isolated from bovine thymus in the 1960s by biochemist Allan Goldstein and colleagues. Later work established that the protein is present in platelets, leukocytes, and wound fluid. In active wounds, the local concentration of Tβ4 reaches five to ten times that of circulating plasma — an observation that drew researchers toward its possible role in tissue repair.

The best-documented molecular mechanism of Tβ4 is sequestration of G-actin monomers. The protein contains the sequence LKKTETQ, recognised as an actin-binding domain. By binding those monomers, Tβ4 regulates cytoskeletal polymerisation and, with it, cell processes that depend on actin reorganisation: division, migration, adhesion, and the formation of new tissue structures.

The name TB-500 refers to the synthetic analogue of the full Tβ4 sequence. Published scientific literature uses Tβ4 almost exclusively; TB-500 is the term most commonly used in the research supply market for the synthetic product.

Active research areas

Cardiac repair

A paper published in *Nature* by Bock-Marquette et al. (2004) showed that Tβ4 activated cardiac progenitor cells in infarcted mice and improved ventricular function at four weeks, compared with saline-treated controls. The authors identified integrin-linked kinase (ILK) as the mediating molecule: Tβ4 bound ILK, promoted its activity, and triggered the survival and migration of cardiomyocytes. That paper was among the first to define a molecular mechanism for Tβ4's effect in damaged cardiac tissue.

Later studies evaluated Tβ4 on ventricular function in longer-duration infarct models and dilated cardiomyopathy models, with consistent findings of reduced infarct zone size and improved ejection fraction.

Angiogenesis and wound healing

Tβ4 stimulates endothelial cell migration and vascular tube formation in in vitro cultures. Animal studies of cutaneous wounds documented that Tβ4 application accelerated wound contraction and re-epithelialisation, with upregulation of pro-angiogenic factors including VEGF. Studies of corneal wound healing reported similar findings in models of superficial injury.

The high concentration of Tβ4 in wound fluid is consistent with an active role in early repair of damaged tissue, though the exact regulatory mechanisms remain under investigation.

Inflammatory response

Tβ4 inhibits NFκB transcription factor activation and reduces production of pro-inflammatory cytokines — particularly IL-1β and TNF-α — in cell models. That property led to research in autoimmune disease models. Studies in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis, reported reduced demyelination and axonal damage in Tβ4-treated animals, with anti-inflammatory activity and stimulation of remyelination proposed as mechanisms.

Neuroprotection

Studies in murine brain ischaemia models found that Tβ4 administration reduced infarct area and improved performance in motor function tests. Authors proposed that promotion of cerebral angiogenesis and activation of neuroplasticity mechanisms accounted for part of the observed results. This research area remains active, with current focus on spinal cord injury and peripheral neuropathy models.

All of this evidence comes from preclinical models. No Phase III clinical trial has been completed and approved by any regulatory authority demonstrating efficacy of Tβ4 or TB-500 in humans for any condition.

TB-500 and BPC-157 in the literature

In PeptoClinic's catalogue, TB-500 and BPC-157 are the two peptides that appear together most often in research orders covering tissue repair models. Published work has studied both compounds in the context of tendon and muscle injuries in animal models. Their mechanisms of action are distinct: BPC-157 acts primarily through growth hormone signalling and the nitric oxide pathway, while TB-500 operates mainly through the actin cytoskeleton. Rigorous studies evaluate each compound separately before proposing combinations.

Batch documentation

PeptoClinic supplies TB-500 with an analytical report from Janoshik Analytical, the reference laboratory for research peptide analysis. The available lot was analysed on 13 April 2026 (task 204975): a 10 mg vial containing 5 mg of TB-500 and 5 mg of BPC-157, with identity and content analysis for each component separately.

Documentation is available before dispatch. To review which reports are available and how to read them, see PeptoClinic's quality page.

Laboratory research material only

TB-500 is supplied as Research Use Only (RUO) material, intended exclusively for in vitro and laboratory research. It is not a medicine, a supplement, or a food. It holds no approval from the FDA, ANMAT, or any equivalent authority for use in humans or animals. PeptoClinic does not write or provide administration protocols for people, does not indicate use amounts, and does not offer clinical guidance of any kind. Requests of that nature are declined.